Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1E | P28566 | 1/20 | 0.62 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.62 |
| ▸ | METAP2 | P50579 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | HPN | P05981 | 6/20 | 0.57 |
| ▸ | PLAU | P00749 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | METAP1 | P53582 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6714050 | 1.00 | HTR1E (0.62) | HTR1ES1PR3METAP2NPC1RAB9A | |
| SCHEMBL6714054 | 1.00 | HTR1E (0.62) | HTR1ES1PR3METAP2NPC1RAB9A | |
| SCHEMBL20866546 | 0.84 | HTR1E (0.62) | HTR1ES1PR3METAP2NPC1RAB9A | |
| SCHEMBL29069770 | 0.84 | EPHX1 (0.59) | HTR1ES1PR3METAP2RAB9AEPHX1 | |
| SCHEMBL29069766 | 0.84 | EPHX1 (0.59) | HTR1ES1PR3METAP2RAB9AEPHX1 | |
| Hydrochloric Acid SCHEMBL27150944 | 0.83 | HTR1E (0.63) | HTR1ES1PR3METAP2RAB9AEPHX1 | |
| Hydrochloric Acid SCHEMBL27150943 | 0.83 | HTR1E (0.63) | HTR1ES1PR3METAP2RAB9AEPHX1 | |
| SCHEMBL29069834 | 0.80 | AAK1 (0.48) | HTR1ES1PR3METAP2NPC1RAB9A | |
| SCHEMBL29069829 | 0.80 | AAK1 (0.48) | HTR1ES1PR3METAP2NPC1RAB9A | |
| SCHEMBL26910005 | 0.80 | AAK1 (0.48) | HTR1ES1PR3METAP2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
| WO-2004022534-A1 | ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS | NPS ALLELIX CORP. (CA) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | SLC1A2, SLC6A7, SLC1A1 | HTR1E 295/4885S1PR3 2698/4885METAP2 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.